For management of a suspected drug overdose, contact your regional Poison Control Centre.
There is little information on acute or chronic overdosage with GENOTROPIN (somatropin for injection). It is known that intravenously administered growth hormone has been shown to result in an acute decrease in plasma glucose and subsequently to hyperglycemia. It is thought that the same effect might occur on rare occasions with high dosages of GENOTROPIN administered subcutaneously or intramuscularly.
Long-term overdosage may result in signs and symptoms of acromegaly consistent with overproduction of human growth hormone.
Route of Administration
Dosage Form / Strength
Clinically Relevant Non-medicinal Ingredients
Available as 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1.0 mg, 1.2 mg, 1.4 mg, 1.6 mg, 1.8 mg, and 2.0 mg Single Dose Syringe, With Sterile Powder and liquid
For a complete listing see Dosage Forms, Composition and Packaging section.
Available as 5 mg, 5.3 mg, 12 mg Multidose disposable pre-filled pen, With Sterile Powder and liquid
GENOTROPIN (somatropin for injection) is a polypeptide hormone of recombinant DNA origin. It has 191 amino acid residues, a molecular weight of 22,124 daltons, and an isoelectric point (pH) of 5.0. The amino acid sequence of the product is identical to that of human growth hormone of pituitary origin (somatropin). GENOTROPIN is synthesized in a strain of Escherichia coli that has been modified by the addition of the gene for human growth hormone.
GENOTROPIN (somatropin for injection) is indicated for:
The long‑term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone (growth hormone deficiency (GHD)). Other causes of short stature should be excluded.
GENOTROPIN is indicated for the treatment of growth failure (current height standard deviation score [SDS] < - 2) in short children born SGA (birth weight and/or length below -2 SD) and who fail to achieve catch-up growth (height velocity SDS < 0 during the last year) by 2 to 4 years or later.
The treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed.
The long-term treatment of idiopathic short stature (ISS), also called non-growth hormone-deficient short stature, defined by height standard deviation score (SDS) <-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means. Genotropin treatment for ISS should be prescribed only for those patients whose epiphyses are not closed.
GENOTROPIN is indicated for the treatment of pediatric patients who have growth failure due to Prader-Willi syndrome (PWS). The diagnosis of PWS should be confirmed by appropriate genetic testing. GENOTROPIN is also indicated for improvement of body composition in children with Prader-Willi syndrome.
GENOTROPIN (somatropin [rDNA origin] for injection) is indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency who meet either of the following two criteria:
Adult Onset (AO): Patients who have growth hormone deficiency, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
Childhood Onset (CO): Patients who were growth hormone deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes.
Patients who were treated with somatropin for growth hormone deficiency in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin therapy at the reduced dose level recommended for growth hormone deficient adults. According to current standards, confirmation of the diagnosis of adult growth hormone deficiency in both groups involves an appropriate growth hormone provocative test with two exceptions: (1) patients with multiple other pituitary hormone deficiencies due to organic disease; and (2) patients with congenital/genetic growth hormone deficiency.
The safety and effectiveness of GENOTROPIN in patients aged 65 and over have not been evaluated in clinical studies. (see WARNINGS AND PRECAUTIONS, Special Populations, Geriatrics).
GENOTROPIN (somatropin for injection) should not be used when there is any evidence of neoplastic activity. Intracranial lesions must be inactive and antitumour therapy complete prior to the institution of therapy. GENOTROPIN should be discontinued if there is evidence of tumour growth.
Growth hormone should not be used for growth promotion in children with fused epiphyses.
Somatropin is contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy.
GENOTROPIN is contraindicated in patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure. (see WARNINGS AND PRECAUTIONS).
GENOTROPIN is contraindicated in patients with a history of hypersensitivity to any of its components.
GENOTROPIN is contraindicated in patients with Prader-Willi syndrome who have uncontrolled diabetes, or active psychosis, or have active cancer.
GENOTROPIN is contraindicated in patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients. (see SERIOUS WARNINGS AND PRECAUTIONS).
Certain formulations of growth hormones contain metacresol as a preservative. These formulations should not be used by patients with a known sensitivity to these preservatives (see WARNINGS AND PRECAUTIONS, General).
Serious Warnings and Precautions
Patients and caregivers who administer GENOTROPIN should receive appropriate training and instruction on the proper use of GENOTROPIN from the physician or suitably qualified health professional.
The 5 mg, 5.3 mg and 12 mg presentations of GENOTROPIN GoQuick lyophilized powder contain m-cresol as a preservative. These products should not be used by patients with a known sensitivity to this preservative. The GENOTROPIN MiniQuick presentations are preservative-free.
Myositis is a very rare adverse event that may be related to the preservative m-cresol. If myalgia or disproportionate pain at injection site develops, myositis should be considered and, if confirmed, a presentation of somatropin without m-cresol should be used.
The site of SC injections of GENOTROPIN should be rotated daily between the thigh, buttocks and abdomen in order to avoid lipoatrophy.
It is recommended that insulin-like growth factor‑I (IGF‑I) concentrations be monitored regularly and maintained within the normal range for age and sex.
To avoid transmission of disease, GENOTROPIN cartridges must not be used by more than one person.
Increased mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure has been reported after treatment with pharmacologic amounts of somatropin (see CONTRAINDICATIONS). The safety of continuing somatropin treatment in patients receiving replacement doses for approved indications who concurrently develop these illnesses has not been established. Therefore, the potential benefit of treatment continuation with somatropin in patients having acute critical illnesses should be weighed against the potential risk.
The effects of GENOTROPIN on recovery were studied in two placebo controlled trials involving 522 critically ill adult patients suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma or acute respiratory failure. Mortality was higher in patients treated with daily doses of 5.3 or 8 mg GENOTROPIN compared to patients receiving placebo, 42% vs. 19%. Based on this information, these types of patients should not be treated with GENOTROPIN.
Carcinogenesis studies have not been conducted with rhGH. rhGH is not expected to be carcinogenic in human as the rhGH molecule is identical to the native hormone and the treatment is substitution therapy. No potential mutagenicity of rhGH was revealed in a battery of tests including the Ames test, a test designed to demonstrate chromosome damaging potential, induction of gene mutations in mammalian cells (L5178Y) in vitro and in intact bone marrow cells (rats).
Leukemia has been reported in a small number of growth hormone-deficient patients, treated with growth hormone, including growth hormone of pituitary origin as well as of recombinant DNA origin (somatrem and somatropin). Based on the current evidence, experts cannot conclude that growth hormone therapy is responsible for these occurrences.
Patients treated with growth hormone may have an increased risk of developing neoplasm.
Patients with pre-existing tumours or with GHD secondary to an intracranial lesion should be examined frequently for progression or recurrence of the underlying disease process.
In pediatric patients, clinical literature has revealed no relationship between somatropin replacement therapy and central nervous system (CNS) tumour recurrence or new extracranial tumours. However, in childhood cancer survivors, an increased risk of a second neoplasm has been reported in patients treated with somatropin after their first neoplasm. Intracranial tumours, in particular meningiomas were the most common of these second neoplasms especially in patients treated with radiation to the head. In adults, it is unknown whether there is any relationship between somatropin replacement therapy and CNS tumour recurrence. Patients should be monitored carefully for any malignant transformation of skin lesions.
Somatropin should not be used for growth promotion in pediatric patients with closed epiphyses.
Treatment of pediatric growth disorders with growth hormones should be discontinued when the patient has reached satisfactory adult height, or when the epiphyses are closed.
There have been reports of fatalities associated with the use of growth hormone in pediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of respiratory impairment or sleep apnea, or unidentified respiratory infection. Another possible risk factor may be male gender. (see CONTRAINDICATIONS).
Patients with Prader Willi syndrome should be evaluated for signs of upper airway obstruction and sleep apnea before initiation of treatment with somatropin.
If a somatropin treated patient shows signs of upper airway obstruction (including onset of or increased snoring) and /or new onset of sleep apnea, somatropin treatment should be interrupted and the patient should be treated for upper airway obstruction and/or sleep apnea.
All patients with Prader Willi syndrome treated with somatropin should also have effective weight control and be monitored for signs of respiratory infection, which should be diagnosed as early as possible and treated aggressively (see CONTRAINDICATIONS).
Progression of scoliosis can occur in patients who experience rapid growth. Because growth hormone increases growth rate, physicians should be alert to this abnormality, which may manifest during growth hormone therapy. Scoliosis is commonly seen in patients with Prader-Willi syndrome.
Patients with Turner syndrome may be at increased risk for development of intracranial hypertension. Therefore, these patients should be evaluated for signs and symptoms of intracranial hypertension and, if present, this condition should be treated before initiation of treatment with somatropin.
Patients with Turner syndrome should be evaluated carefully for otitis media and other ear disorders before and during treatment with somatropin because these patients have an increased risk of ear and hearing disorders (see ADVERSE REACTIONS).
Patients with Turner syndrome are at risk for cardiovascular disorders (e.g. hypertension, stroke, and aortic dilatation, aneurysm and dissection) and these patients should be monitored closely for development or worsening of these conditions before and during treatment with somatropin.
Patients with Turner syndrome have an inherently increased risk of developing autoimmune thyroid disease. Therefore, these patients should have periodic thyroid function tests performed and be treated appropriately (see Endocrine and Metabolism).
Note: Skeletal abnormalities including scoliosis are commonly seen in untreated patients with Turner syndrome.
GENOTROPIN is not considered to be a drug that has potential to produce drug dependency. GENOTROPIN does not have stimulant, depressant or hallucinogenic effects on the central nervous system that could be expected to lead to psychological or physical dependency.
Potential for Misuse: Inappropriate use of somatropin by individuals who do not have indications for which somatropin is approved, may result in clinically significant negative health consequences.
Patients with diabetes mellitus or glucose intolerance should be monitored closely during therapy with somatropin, as an adjustment of their antidiabetic therapy may be required.
Treatment with somatropin may decrease insulin sensitivity, particularly at higher doses in patients with risk factors for diabetes mellitus, such as obesity, Turner syndrome, or a family history of diabetes mellitus, those receiving high dose corticosteroid therapy, and patients with impaired glucose tolerance or pre‑existing diabetes mellitus. As a result, previously undiagnosed impaired glucose tolerance and overt diabetes mellitus may be unmasked during somatropin treatment. Therefore, patients who receive somatropin should be monitored for evidence of abnormal glucose metabolism and/or diabetes mellitus. New‑onset type 2 diabetes mellitus has been reported in children and adults receiving somatropin.
In patients with hypopituitarism standard hormonal replacement therapy should be monitored closely when somatropin therapy is administered.
Somatropin can increase the extrathyroidal conversion of thyroxine (T4) to triiodothyronine (T3) and may unmask incipient hypothyroidism. Because inadequate treatment of hypothyroidism may prevent optimal response to somatropin, thyroid function should be evaluated before starting somatropin therapy and should be monitored regularly during treatment, not less frequently than annually.
Notes Regarding Potential Effects of Somatropin on Glucocorticoid Metabolism: The microsomal enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1) is required for conversion of cortisone to its active metabolite, cortisol in hepatic and adipose tissue. Endogenous growth hormone and exogenous somatropin inhibit the activity of 11βHSD-1. Therefore growth hormone deficiency is associated with a relative increase in 11βHSD-1 activity, which in turn results in a relative increase in serum cortisol. Somatropin treatment may inhibit 11βHSD-1, resulting in relative reduction of serum cortisol concentrations.
In addition, somatropin may enhance the activity of CYP3A4, a cytochrome P450 enzyme involved in glucocorticoid catabolism. Therefore, by increasing the activity of CYP3A4, somatropin could potentially decrease serum cortisol concentration. Because somatropin may both inhibit 11βHSD-1 (an enzyme required for production of cortisol) and induce activity of CYP3A4 (an enzyme involved in cortisol breakdown), careful monitoring of serum cortisol concentrations is required for all patients receiving concomitant glucocorticoid and somatropin therapy.
As a consequence of its actions on enzymes involved in cortisol metabolism, somatropin treatment may unmask previously undiagnosed central (secondary) hypoadrenalism, and glucocorticoid replacement may be required. In addition, patients treated with glucocorticoids for previously diagnosed hypoadrenalism (primary or secondary) may require adjustments of their maintenance or stress doses following initiation of somatropin treatment; this may be especially true for patients treated with cortisone acetate and prednisone, because conversion of these drugs to their biologically active metabolites is dependent on the activity of 11βHSD-1 (see Monitoring and Laboratory Tests).
Fluid retention during somatropin replacement therapy in adults may occur. Clinical manifestations of fluid retention are usually transient and dose dependent.
Patients receiving somatropin treatment may experience redness, swelling, pain, inflammation, or itching at the site of injection (see ADVERSE REACTIONS).
Most of these minor reactions usually resolve in a few days to a few weeks. Such reactions may occur if the injection is given incorrectly (irritants in the skin cleansing agent or poor injection technique), or if the patient is allergic to somatropin or any non-medicinal ingredient (see CONTRAINDICATIONS).
Rarely, subcutaneous administration of somatropin can result in lipoatrophy or lipohypertrophy. Regular rotation of the injection site may help reduce or prevent these reactions.
Patients should be advised to consult their doctor if they notice any of the conditions described above.
On rare occasions, injection site reactions may require discontinuation of somatropin therapy.
As with any protein, local or systemic allergic reactions may occur. Parents/patients should be informed that such reactions are possible and that prompt medical attention should be sought if allergic reactions occur.
These reactions may be characterized by a generalized rash (with pruritus), shortness of breath, wheezing, angioneurotic edema and drop in blood pressure (see ADVERSE REACTIONS).
Severe cases of generalized allergy including anaphylactic reaction may be life threatening (see CONTRAINDICATIONS).
If any serious hypersensitivity or allergic reaction occurs, somatropin therapy should be discontinued immediately and appropriate therapy initiated.
Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with post-marketing use of somatropin products. Patients and caregivers should be informed that such reactions are possible and that prompt medical attention should be sought if an allergic reaction occurs (see CONTRAINDICATIONS).
A small percentage of patients treated with somatropin may develop antibodies during treatment that could potentially reduce treatment response (see ADVERSE REACTIONS).
Patients who have demonstrated an allergic reaction to other somatropin products may demonstrate an allergic reaction to GENOTROPIN.
Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea and/or vomiting has been reported in a small number of patients treated with growth hormone products. Symptoms usually occurred within the first eight weeks of initiation of growth hormone therapy. In all reported cases, IH-associated signs and symptoms resolved after termination of therapy or a reduction of growth hormone dose. Fundoscopic examination of patients is recommended at the initiation, and periodically during the course of, growth hormone therapy. If papilledema is observed by funduscopy during somatropin treatment, treatment should be stopped. If somatropin-induced IH is diagnosed, treatment with somatropin can be restarted at a lower dose after IH associated signs and symptoms have resolved. Patients with Turner syndrome may be at increased risk for the development of IH.
Musculoskeletal discomfort (pain, swelling and/or stiffness) may occur during treatment with somatropin (see ADVERSE REACTIONS). These symptoms may resolve spontaneously, with analgesic therapy, or after reducing the dosage (see DOSAGE AND ADMINISTRATION).
Swelling of the hands and feet may occur during treatment with somatropin and may lead to carpal tunnel syndrome, which may be improved by decreasing the dosage of somatropin.
Somatropin has not been shown to increase the occurrence of scoliosis. However, progression of pre existing scoliosis can occur in pediatric patients who experience rapid growth. Therefore, because somatropin increases growth rate, patients with a history of scoliosis who are treated with somatropin should be monitored for progression of scoliosis.
Slipped capital femoral epiphysis may occur more frequently in patients with endocrine disorders (including pediatric growth hormone deficiency, Turner syndrome and hypothyroidism) or in patients undergoing rapid growth. Any pediatric patient with the onset of a limp or complaints of hip or knee pain during somatropin therapy should be carefully evaluated (see Monitoring and Laboratory Tests).
Cases of pancreatitis have been reported rarely in children and adults receiving somatropin treatment, with some evidence supporting a greater risk in children compared with adults. Pancreatitis should be considered in any somatropin treated patients, especially a child, who develops persistent severe abdominal pain.
Somatropin doses may need to be adjusted in patients with renal and/or hepatic and/or biliary and/or pancreatic impairments.
No adequate and well-controlled clinical studies with GENOTROPIN on reproductive function have been performed (see Special Populations, Pregnant Women)
Animal reproductive studies in rats and rabbits treated during the period of organogenesis have not given evidence of any harmful effects on the fetus. There are however, no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Patients and/or their caregivers should be informed about potential advantages and disadvantages of GENOTROPIN therapy including the possible side effects. It should be noted that although serious adverse events may be rare, their occurrence needs to be outweighed by the benefits.
If home use is determined to be desirable by the physician, patients should also be offered instruction for use of injection devices, storage, travelling and other pertinent information. (see CONSUMER INFORMATION, INSTRUCTION FOR USE).
Pregnant Women: There are no adequate and well controlled studies of GENOTROPIN treatment in pregnant women. Therefore, the safety of GENOTROPIN has not been established in this subpopulation. It is not known whether GENOTROPIN can cause fetal harm when administered to a pregnant woman. GENOTROPIN should be given to a pregnant woman only if the benefits clearly outweigh the risks and only under medical supervision.
Female patients should be advised to inform their doctor if they are, or become pregnant, or are contemplating pregnancy.
Nursing Women: There is no experimental data available that suggests whether peptide hormones, such as growth hormone, pass over into the breast milk but absorption in the gastrointestinal tract of the infant of intact protein is extremely unlikely.
Obese patients: Obese individuals are more likely to manifest adverse effects when treated with a weight-based regimen (see DOSAGE AND ADMINISTRATION).
Pediatric Patients: (see INDICATIONS AND CLINICAL USE)
Children who have endocrine disorders, including growth hormone deficiency, may develop slipped capital femoral epiphyses more frequently than children in the general population. Any pediatric patient with onset of a limp during somatropin therapy should be evaluated.
Note: Some of the height gain obtained with somatropin treatment may be lost if treatment is stopped before final height is reached.
Turner Syndrome: see Congenital Disorders.
Idiopathic Short Stature: Other medical reasons or treatments that could explain growth disturbance should be ruled out before starting GENOTROPIN treatment for children with idiopathic short stature. GENOTROPIN treatment for idiopathic short stature should be prescribed only for those patients whose epiphyses are not closed and should be managed by physicians who have sufficient knowledge of idiopathic short stature and the efficacy/safety profile of GENOTROPIN.
Small for Gestational Age: In short children born small for gestational age (SGA) other medical reasons or treatments that could explain growth disturbance should be ruled out before starting treatment with somatropin (GENOTROPIN). Experience with SGA patients with Silver-Russell syndrome is limited, as is experience in initiating treatment in SGA patients near onset of puberty.
In short children born SGA, it is recommended that IGF-I concentration should be measured before initiation of treatment and monitored every 6 months thereafter. If on repeated measurements IGF-I concentrations exceed +2 SD compared to references for age and pubertal status, the IGF-I/IGFBP-3 ratio could be taken into account to consider dose adjustment.
Adult Patients: Patients with ephiphyseal closure who were treated with somatropin therapy in childhood should be re‑evaluated according to the criteria provided in INDICATIONS AND CLINICAL USE before continuation of somatropin therapy at the reduced dose level required for growth hormone‑deficient adults.
Experience with prolonged treatment in adults is limited. Adverse events such as peripheral edema, myalgia, arthralgia, and paresthesiae have been reported during post‑marketing studies (see ADVERSE REACTIONS).
Growth hormone deficiency in the adult is a lifelong condition and should be treated accordingly. Experience with patients over sixty years of age is limited.
Note: Based on assessment of clinical trial data, post‑marketing data, and spontaneous reports carpal tunnel syndrome appears to occur more frequently in patients over 40 years of age than in younger patients. In almost half of the reported cases the recommended maximum somatropin dose had been exceeded. In the majority of cases, the condition resolved spontaneously or with a decrease in dosage, interruption of treatment, or discontinuation of treatment. The maximum recommended dosage should not be exceeded.
Geriatrics: The safety and effectiveness of GENOTROPIN in patients aged 65 and over have not been evaluated in clinical studies. Elderly patients may be more sensitive to the action of GENOTROPIN, and therefore may be more prone to develop adverse reactions. A lower starting dose and smaller dose increments should be considered for older patients.
Serum levels of inorganic phosphorus, alkaline phosphatase, parathyroid hormone (PTH) and IGF-I may increase during somatropin therapy.
Adults: Adult patients, during GH treatment, should be monitored at 1- to 2-month intervals during dose titration and every 6 months thereafter with clinical assessment, evaluation for adverse effects, IGF-I levels, and other parameters of GH response. Other laboratory testing should include a lipid profile and a fasting glucose. These should be assessed annually.
Patients with an intra- or extra-cranial neoplasm in remission who are receiving treatment with somatropin should be examined carefully and at regular intervals by the physician. In case of persistent edema or severe paraesthesia the dosage should be decreased in order to avoid the development of carpal tunnel syndrome (see ADVERSE REACTIONS).
Children: Children, during GH treatment, should be monitored every 3 to 6 months with measurement of IGF-1/IGFBP-3 levels and clinical assessment expressed as increase in height (SD per year) and change in height velocity.
Bone age should be monitored periodically during somatropin administration.
Patients with an intra- or extra-cranial neoplasm in remission who are receiving treatment with somatropin should be examined carefully and at regular intervals by the physician.
In short children born SGA, it is recommended that IGF I concentration be measured before initiation of treatment and monitored every 6 months thereafter. If on repeated measurements IGF-I concentrations exceed +2 SD compared to references for age and pubertal status, the IGF-I/IGFBP-3 ratio could be taken into account to consider dose adjustment.
Patients with growth hormone deficiency are characterized by extracellular volume deficit. When treatment with somatropin is started this deficit is rapidly corrected. In adult patients adverse effects related to fluid retention, such as peripheral edema, face edema, stiffness in the extremities, arthralgia, myalgia and paraesthesia are common. In general these adverse effects are mild to moderate, arise within the first months of treatment and subside spontaneously or with dose-reduction. Severe hypersensitivity has been reported in post-marketing use of somatropin products.
The incidence of these adverse effects is related to the administered dose, the age of patients, and possibly inversely related to the age of patients at the onset of growth hormone deficiency. In children such adverse effects are uncommon.
Somatropin has been reported to reduce serum cortisol levels, possibly by affecting carrier proteins or by increased hepatic clearance. The clinical relevance of these findings may be limited. Nevertheless, corticosteroid replacement therapy should be optimised before initiation of GENOTROPIN (somatropin for injection) therapy (see WARNINGS AND PRECAUTIONS, Endocrine and Metabolism).
Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to GENOTROPIN with the incidence of antibodies to other products may be misleading. In the case of growth hormone, antibodies with binding capacities lower than 2 mg/mL have not been associated with growth attenuation. In a very small number of patients treated with somatropin, when binding capacity was greater than 2 mg/mL, interference with the growth response was observed.
In 419 pediatric patients evaluated in clinical studies with GENOTROPIN lyophilized powder, 244 had been treated previously with GENOTROPIN or other growth hormone preparations and 175 had received no previous growth hormone therapy. Antibodies to growth hormone (anti-hGH antibodies) were present in six previously treated patients at baseline. Three of the six became negative for anti-hGH antibodies during 6 to 12 months of treatment with GENOTROPIN. Of the remaining 413 patients, eight (1.9%) developed detectable anti-hGH antibodies during treatment with GENOTROPIN; none had an antibody binding capacity > 2 mg/L. There was no evidence that the growth response to GENOTROPIN was affected in these antibody-positive patients.
Clinical Trials in children with GHD In clinical studies with GENOTROPIN in children, the following events were reported infrequently: injection site reactions, e.g. pain or burning associated with the injection, fibrosis, nodules, rash, inflammation, pigmentation; bleeding; lipoatrophy; headache; hematuria; hypothyroidism; mild hyperglycemia.
Clinical Trials in children with SGA In clinical studies of 273 pediatric patients born small for gestational age treated with GENOTROPIN, the following clinically significant events were reported: mild transient hyperglycemia, one patient with benign intracranial hypertension, two patients with central precocious puberty, two patients with jaw prominence, and several patients with aggravation of preexisting scoliosis, injection site reactions, and self-limited progression of pigmented nevi. IGF-I levels ranged from <20ng/ml to 593 ng/ml.
Anti-GH antibodies were assessed at baseline, 12 and 24 months in Genotropin-treated SGA children enrolled in study 89-041. At 12 months, the study included 27 untreated SGA children, 59 SGA children treated with Genotropin at a dose of 33 µg/kg body weight/day and 51 short SGA children treated with Genotropin at a dose of 67µg/kg body weight/day. At 24 months, the study included 10 untreated SGA children, 62 short SGA children treated with Genotropin at a dose of 33 µg/kg body weight/day (including 9 children who received no treatment during the first 12 months of the study) and 56 SGA children treated with Genotropin at a dose of 67 µg/kg body weight/day (including 8 children who received no treatment during the first 12 months of the study). None of these patients were determined to be positive for anti-GH antibodies at baseline or at any time during the course of the 24 months of the study.
Body system / Preferred Term
0.033 mg/kg/day N=105
0.067 mg/kg/day N=117
0.1 mg/kg/day N=19
Skin & Appendage
Central & Peripheral Nervous System
Hearing & Vestibular system
Ear disorder nos
Metabolism and Nutritional
Upper respiratory tract infection
Red Blood Cell
Injection site reaction
Tympanic membrane perforation
Clinical trial adverse drug reactions with a frequency of less than 1% are presented in the following listing: Skin & Appendage disorders: eczema Musculoskeletal disorders: bone development abnormal, spine malformation Central and Peripheral nervous system disorders: ataxia Psychiatric disorders: aggressive reaction, concentration impaired Gastrointestinal disorders: abdominal pain, malabsorption Endocrine disorders: gynaecomastia, puberty precocious Respiratory disorders: sinusitis Urinary disorders: dysuria General disorders: hepatomegaly
Clinical trial adverse drug reactions with a frequency of less than 1% are presented in the following listing: Skin & Appendage disorders: acne, nail disorder, pruritus, skin dry, sweating increased, urticaria Musculoskeletal disorders: arthralgia, fracture, spine malformation Central and Peripheral nervous system disorders: absences, headaches Vision: conjunctivitis Hearing and Vestibular system disorders: earache Gastrointestinal disorders: abdominal pain, anorexia, enteritis Metabolism and nutritional system disorders: hypoglycemia Endocrine disorders: puberty precocious Extra cardiac: vein distended Respiratory disorders: thyroid adenoma Red blood cell: anemia White blood cell: lymphadenopathy Platelet/bleed disorder: purpura, thrombocytopenia Urinary disorders: cystitis, urinary tract infection, urogenital malformation Neoplasm disorder: neoplasm nos General disorders: accident
Central & Peripheral Nervous System
Muscle contractions involuntary
Hearing & Vestibular System
Metabolic & Nutritional
Red blood cell
Urinary tract infection
Deviating laboratory value
Inflammatory reaction nos
Injection site atrophy
Injection site fibrosis
Clinical trial adverse drug reactions that lead to treatment termination are listed below by dose group: 0.033 mg/kg/day: Thrombocytopenic purpura 0.067 mg/kg/day: Aggressive reaction, Ataxia, Retinal dystrophy (2 patients) Discontinuous therapy: Diabetes mellitus, Surgical intervention, Muscle malformation.
Respiratory Adverse Events in children with SGA In the open- label SGA studies, the percentage of respiratory adverse events for the 3 active treatment groups (16.2% in 0.033 mg/kg/day, 20.5% in 0.067 mg/kg/day and 26.3% in 0.1 mg/kg/day) were higher than in the untreated group (10.5%) between 0 - 12 months. Between 12 - 24 months, the incidence of respiratory events was also higher in the 3 active treatment groups (18.9% in 0.033 mg/kg/day; 13.6% in 0.067 mg/kg/day; 21.1% in 0.1 mg/kg/day) compared to 7.5% in the untreated control group. Respiratory adverse events included mostly upper respiratory tract infections. Adverse events classified as 'resistance mechanism' which included viral infection, otitis media, and pharyngitis occurred at a higher rate in 2 of the active treatment groups (21.9% in 0.033 mg/kg/day; 19.7% in 0.067 mg/kg/day; 0% in 0.1 mg/kg/day) compared to the untreated control group (15.8%) between 0 - 12 months. Between 12 - 24 months, the incidence of resistance mechanism adverse events was higher in all 3 active treatment groups (25.5% in 0.033 mg/kg/day; 16.1% in 0.067 mg/kg/day; 31.6% in 0.1 mg/kg/day) compared to 13.2% in the untreated control group. However, none of the differences among the four study groups were evaluated for statistical significance.
The adverse events most frequently reported for the study periods were: viral infections, otitis media, pharyngitis, upper respiratory tract infections, and rhinitis. Overall, these events were consistent with the pattern of normal childhood illnesses in this age group. No evidence of a dose-related pattern was apparent. There were a higher number of patients in 2 of the somatropin-treated groups (0.033 mg/kg/day, n=105; 0.067 mg/kg/day, n=117) than in the untreated group (n=76); however the highest dose group (0.1 mg/kg/day) had only 19 patients. While, the investigators did not consider these events to be treatment-related, this cannot be ruled out.
Table 4 summarizes the frequencies of subjects with IGF-I levels below/above or within normal range, organized for all treatment groups side-by-side and across all visits from CTN 89-041 (France). Subject groups Untreated/0.033 mg/kg/wk and Untreated/0.067 mg/kg/wk include subjects who served as untreated controls for 12 months or longer, and were subsequently treated with Genotropin 0.033 mg/kg/wk or 0.067 mg/kg/wk, respectively. In figure 1, the solid reference lines were created by averaging individual upper and lower limits of normal ranges across all subjects with observed IGF-I levels at a given time-point. As such, the reference lines are for overall inference, as they represent an approximation of the exact normative values. As can be seen in the various graphs, IGF-1 levels generally ranged from <20ng/ml to 593 ng/ml.
Clinical Trials in children with Turner Syndrome In two clinical studies with GENOTROPIN in pediatric patients with Turner syndrome, the most frequently reported adverse events were respiratory illnesses (influenza, tonsillitis, otitis, sinusitis), joint pain, and urinary tract infection. The only treatment-related adverse event that occurred in more than 1 patient was joint pain. In one study in children with TS, none of the 42 patients discontinued from the study early while in the second study, none of the patients discontinued before 18 months.
WHO Dictionary Term
Genotropin plus ethinyloestradiol
Urinary Tract Infection
WHO dictionary term
Genotropin + oxandrolone
Skin and appendage disorders
Loss of hair
Musculo-skeletal system disorders
Hearing and vestibular disorders
2 (11.8 %)
Liver and biliary system
Metabolic and nutritional disorders
Insulin value increased
Vascular (extra cardiac) disorders
White cell and res disorders
Platelet, bleeding and clotting disorders
Urinary system disorders
Body as a whole – General disorders
Clinical Trials in children with Turner’s syndrome In one study with patients with TS, respiratory infections (otitis, tonsillitis, sinusitis, influenza, bronchitis) represented the majority of adverse events in children with TS with eight patients in the Genotropin group and 11 patients in the Genotropin and oxandrolone groups. The instances of the respiratory infections were assessed as unrelated to study drug. No patient discontinued treatment due to a treatment related adverse event. Younger patients, including patients with TS, treated or untreated, are known to have generally greater incidence of otitis media and ear problems.
In a second study, one patient experienced sinusitis, orbital cellulitis and grand mal seizure. These events were considered to be unlikely related to the study drug as per the investigator and they were also low in frequency.
Clinical Trials in children with Idiopathic Short Stature In two open-label clinical studies with GENOTROPIN in pediatric patients with ISS, the most commonly encountered adverse events include upper respiratory tract infections, influenza, tonsillitis, nasopharyngitis, gastroenteritis, headaches, increased appetite, pyrexia, fracture, altered mood, and arthralgia. In one of the two studies, during GENOTROPIN treatment, the mean IGF-1 standard deviation (SD) scores were maintained in the normal range. IGF-1 SD scores above +2 SD were observed as follows: 1 subject (3%), 10 subjects (30%) and 16 subjects (38%) in the untreated control, 0. 23 and the 0.47 mg/kg/week groups, respectively, had at least one measurement; while 0 subjects (0%), 2 subjects (7%) and 6 subjects (14%) had two or more consecutive IGF-1 measurements above +2 SD.
0.033 and 0.067 mg/kg/day
N = 112
N = 61
N = 47
N = 49
N = 46
N = 16
N = 15
Blood and lymphatic system disorders
Iron deficiency anaemia
Congenital, familial and genetic disorders
Ear and labyrinth disorders
Abdominal pain upper
General disorders and administration site conditions
Immune system disorders
Infections and infestations
Otitis media acute
Respiratory tract infection
Upper respiratory tract infection
Urinary tract infection
Injury, poisoning and procedural complications
Lower limb fracture
Road traffic accident
Blood immunoglobulin G decreased
Blood testosterone decreased
Blood thyroid stimulating hormone decreased
Heart rate irregular
Heart sounds abnormal
Thyroxine free decreased
Metabolism and nutrition disorders
Markedly reduced dietary intake
Musculoskeletal and connective tissue disorders
Lower limb deformity
Pain in extremity
Patellofemoral pain syndrome
Nervous system disorders
Disturbance in attention
Nervous system disorder
Petit mal epilepsy
Attention deficit/hyperactivity disorder
Dissociative identity disorder
Renal and urinary disorders
Reproductive system and breast disorders
Respiratory, thoracic and mediastinal disorders
Skin and subcutaneous tissue disorders
Cafe au lait spots
Corrective lens user
Death of parent
Death of relative
Death of sibling
Surgical and medical procedures
Brain tumour operation
Ear tube insertion
Skin neoplasm excision
Includes all Untreated Controls in the Safety Analysis Population.
Upper respiratory infection
Clinical trial adverse drug reactions that lead to treatment termination are listed below: Dissociative identity disorder, pituitary cyst, mood swings and irritability.
N = 18
N = 19
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS
Influenza like illness
Injection site rash
Increased alanine aminotransferase
Increased aspartate aminotransferase
Increased blood insulin
Decreased blood thyroid stimulating hormone
Increased blood thyroid stimulating hormone
Increased blood triglycerides
Eosinophil percentage increased
METABOLISM AND NUTRITION DISORDERS
Impaired glucose tolerance
Trace element deficiency
EAR AND LABYRINTH DISORDERS
Middle ear effusion
INFECTIONS AND INFESTATIONS
Otitis media acute
Viral upper respiratory tract infection
INJURY, POISONING AND PROCEDURAL COMPLICATIONS
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS
NERVOUS SYSTEM DISORDERS
Disturbance in attention
Petit mal epilepsy
RENAL AND URINARY DISORDERS
REPRODUCTIVE SYSTEM AND BREAST DISORDERS
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS
SKIN AND SUBCUTANEOUS TISSUE DISORDERS
SURGICAL AND MEDICAL PROCEDURES
Umbilical hernia repair
Clinical Trials in children with Idiopathic Short Stature In ISS studies, the most frequently encountered respiratory adverse events, seen in ≥5% of subjects, included infections and infestations (upper respiratory tract infections, influenza, tonsillitis, nasopharyngitis).
In the pivotal study, eight of the 15 subjects with upper respiratory infection were in the lower dose Genotropin treatment group (0.033 mg/kg/day; prepubertal) and seven received 0.067 mg/kg/day (six prepubertal and one pubertal).
Influenza occurred in four subjects that received 0.067 mg/kg/day (three prepubertal and one pubertal) and in five subjects that received 0.033 mg/kg/day. Nasopharyngitis was also reported only in prepubertal Genotropin treated subjects (four at 0.033 mg/kg/day and two at 0.067 mg/kg/day).
Clinical Trials in adults with GHD Recurrence of pituitary adenoma and of craniopharyngioma were reported in one case each. In these patient categories tumour recurrence is not uncommon, but it is as yet not possible to compare rates between patients on GH treatment and those without such substitution.
In clinical trials with GENOTROPIN in 1,145 GHD adults, the majority of the adverse events consisted of mild to moderate symptoms of fluid retention, including peripheral swelling, arthralgia, pain and stiffness of the extremities, peripheral edema, myalgia, paresthesia, and hypoesthesia. These events were reported early during therapy, and tended to be transient and/or responsive to dosage reduction.
Table 10 displays the adverse events reported by 5% or more of adult GHD patients in clinical trials after various durations of treatment with GENOTROPIN. Also presented are the corresponding incidence rates of these adverse events in placebo patients during the 6-month double-blind portion of the clinical trials.
* Increased significantly when compared to placebo, P≤.025: Fisher´s Exact Test (one-sided)
n = number of patients receiving treatment during the indicated period.
Double Blind Phase
Open Label Phase
n = 572
n = 573
n = 504
n = 63
n = 60
Stiffness of extremities
Post-Trial Extension Studies in Adults In expanded post-trial extension studies, diabetes mellitus developed in 12 of 3,031 patients (0.4%) during treatment with GENOTROPIN. All 12 patients had predisposing factors, e.g., elevated glycosylated hemoglobin levels and/or marked obesity, prior to receiving GENOTROPIN. Of the 3,031 patients receiving GENOTROPIN, 61 (2%) developed symptoms of carpal tunnel syndrome, which lessened after dosage reduction or treatment interruption (52) or surgery (9). Other adverse events that have been reported include generalized edema and hypoesthesia.
Clinical Trials in children with Prader-Willi SyndromeIn the two clinical studies with GENOTROPIN in pediatric patients with Prader-Willi Syndrome, the most frequently reported adverse events were as reported in table 11.
Nervous System Disorders
Benign Intracranial hypertension
Musculoskeletal, Connective Tissue Disorders and Bone Disorders
General Disorders and Administration
Because these adverse events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The adverse events reported during post-marketing surveillance do not differ from those listed/discussed above (see Clinical Trials Adverse Reactions) in children and adults.
Leukemia has been reported in a small number of GHD children treated with somatropin, somatrem (methionylated rhGH) and GH of pituitary origin. It is uncertain whether these cases of leukemia are related to GH therapy, the pathology of GHD itself, or other associated treatments such as radiation therapy. On the basis of current evidence, experts have not been able to conclude that GH therapy per se was responsible for these cases of leukemia. The risk for children with GHD, if any, remains to be established [see Contraindications and Warnings and Precautions)].
The following additional adverse reactions have been observed during the appropriate use of somatropin: headaches (children and adults), gynecomastia (children), and pancreatitis (see Warnings and Precautions), rash (children and adults), pruritus (children and adults) and urticaria (children and adults).
Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with post marketing use of somatropin products (see CONTRAINDICATIONS and WARNINGS and PRECAUTIONS – Immune).
New-onset type 2 diabetes mellitus has been reported.
Slipped capital femoral epiphysis and Legg-Calve-Perthes disease have been reported in children treated with growth hormone. No causal relationship has been demonstrated with somatropin.
In the post-marketing experience rare cases of sudden death have been reported in patients affected by Prader-Willi syndrome, some of whom were treated with somatropin. No causal relationship has been demonstrated.
No studies on the interactions with other drugs have been performed since recombinant somatropin has the same amino acid sequence as pituitary-derived growth hormone.
Limited published data indicate that growth hormone treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in human. These data suggest that growth hormone administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g. corticosteroids, sex steroids, anticonvulsants, cyclosporine). Careful monitoring is advisable when growth hormone is administered in combination with other drugs known to be metabolized by CP450 liver enzymes.
The microsomal enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. GH and somatropin inhibit 11βHSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11βHSD-1 and serum cortisol. Introduction of somatropin treatment may result in inhibition of 11βHSD-1 and reduced serum cortisol concentrations. As a consequence, previously undiagnosed central (secondary) hypoadrenalism may be unmasked and glucocorticoid replacement may be required in patients treated with somatropin. In addition, patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of somatropin treatment; this may be especially true for patients treated with cortisone acetate and prednisone since conversion of these drugs to their biologically active metabolites is dependent on the activity of 11βHSD-1.
Concomitant glucocorticoid treatment may inhibit the growth promoting effect of human growth hormone. GHD children with coexisting ACTH deficiency should have their glucocorticoid replacement dose carefully adjusted to avoid an inhibitory effect on growth. Therefore, patients treated with glucocorticoids should have their growth monitored carefully to assess the potential impact of glucocorticoid treatment on growth. (see WARNINGS AND PRECAUTIONS – Endocrine and Metabolism and DRUG INTERACTIONS - β-Hydroxysteroid Dehydrogenase Type 1)
Patients with ACTH deficiency should be carefully monitored to avoid adrenal insufficiency.
In patients on oral estrogen replacement, a larger dose of somatropin may be required to achieve the defined treatment goal. If a woman taking somatropin begins oral estrogen therapy, the dose of somatropin may need to be increased to maintain the serum insulin-like growth factor-I (IGF-I) levels within the normal age-appropriate range. However, the maximum recommended weekly dose should not be exceeded.
If a woman on somatropin discontinues oral estrogen therapy, the dose of somatropin may need to be reduced to avoid excess of growth hormone and/or side effects.
In patients with diabetes mellitus requiring drug therapy, the dose of insulin and/or oral/injectable agent may require adjustment when somatropin therapy is initiated (see WARNINGS AND PRECAUTIONS).
Therapy with GENOTROPIN (somatropin for injection) should be supervised by a physician who is experienced in the diagnosis and management of pediatric patients with growth failure associated with growth hormone deficiency (GHD), Turner syndrome (TS), those who were born small for gestational age (SGA) or Idiopathic Short Stature (ISS), and adult patients with either childhood onset or adult onset GHD.
The GENOTROPIN dosage and administration schedule should be individualized based on the growth response of each patient.
Response to somatropin therapy in pediatric patients tends to decrease with time. However, in pediatric patients, the failure to increase growth rate, particularly during the first year of therapy, indicates the need for close assessment of compliance and evaluation for other causes of growth failure, such as hypothyroidism, undernutrition, advanced bone age and antibodies to recombinant human GH (rhGH).
Treatment with GENOTROPIN for short stature should be discontinued when the epiphyses are fused.
The recommended dosage of GENOTROPIN
1GENOTROPIN dosage must be adjusted for the individual patient.
2Final dose should be individually increased as required with respect to age and gender to a maximum daily maintenance dose of 1.33 mg. Women may require higher doses than men. This means that there is a risk that women, especially those on oral estrogen replacement may be under-treated. As normal physiological growth hormone production decreases with age, dose requirements may be reduced.
3 Treatment should stop when near adult height is achieved (height velocity <2cm/yr and/or bone age >16 yr in boys and >14 yr in girls) or when height is in the normal adult range (above -2 SDS).
4GENOTROPIN may be administered in the thigh, buttocks or abdomen; the site of SC injections should be rotated daily to help prevent lipoatrophy
Recommended Dose (mg/kg body weight)
Pediatric Growth Hormone Deficiency1
0.16 - 0.24 mg/kg body weight/week
Divided into 6-7 doses
Diagnosis of GHD should be confirmed before GENOTROPIN is administered.
Adults Growth Hormone Deficiency
0.15 - 0.3 mg/day2
0.33 mg/kg body weight per week
Idiopathic Short Stature1
UP TO 0.47 mg/kg body weight per week3
Small for Gestational Age1
UP TO 0.48 mg/kg body weight per week
Adults Growth Hormone Deficiency Clinical response, side effects and determination of IGF-1 in serum may be used as guidance for dose titration. The level of IGF-1 should not exceed the upper limit of normal IGF-1 levels matched to age and sex.
It is recommended that IGF-I concentrations be monitored regularly and GH dose be reduced in children with a plasma IGF-1 above + 2SD.
Small for Gestational Age Recent literature has recommended initial treatment with larger doses of somatropin (e.g., 0.48 mg/kg/week), especially in very short children (i.e., height SDS <–3), and/or older/ pubertal children, and that a reduction in dosage (e.g., gradually towards 0.24 mg/kg/week) should be considered if substantial catch-up growth is observed during the first few years of therapy. On the other hand, in younger SGA children (e.g., approximately <4 years) with less severe short stature (i.e., baseline height SDS values between -2 and -3), consideration should be given to initiating treatment at a lower dose (e.g., 0.24 mg/kg/week), and titrating the dose as needed over time. In all children, clinicians should carefully monitor the growth response, and adjust the somatropin dose as necessary.
Dosing should continue until final height is reached (see DETAILED PHARMACOLOGY, Human Pharmacology, Pharmacodynamics). Treatment should be discontinued after the first year of treatment if the height velocity SDS is below + 1. Treatment should be discontinued if height velocity is < 2 cm/year and, if confirmation is required, bone age is > 14 years (girls) or > 16 years (boys) corresponding to closure of the epiphyseal growth plates.
In short children born SGA, it is recommended that IGF I concentration be measured before initiation of treatment and monitored every 6 months thereafter. If on repeated measurements IGF-I concentrations exceed +2 SD compared to references for age and pubertal status, the IGF-I/IGFBP-3 ratio could be taken into account to consider dose adjustment.
See CONSUMER INFORMATION for detailed information.
All parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit. If the solution is cloudy, the contents MUST NOT be injected.
GENOTROPIN (somatropin for injection) is a polypeptide hormone of recombinant DNA origin. The amino acid sequence of the product is identical to that of human growth hormone of pituitary origin. GENOTROPIN stimulates linear growth in children with growth hormone deficiency. In vitro, preclinical and clinical tests have demonstrated that GENOTROPIN is therapeutically equivalent to pituitary growth hormone and achieves similar pharmacokinetic profiles in normal adults.
Treatment of growth hormone deficient (GHD) children with GENOTROPIN produces increased growth rate and IGF – I (Insulin like Growth Factor- I) concentrations that are similar to those seen after therapy with pituitary growth hormone.
Treatment of GH deficient adults with GENOTROPIN increases serum IGF-I to normal levels, improves body composition and Quality of Life.
In addition, the following actions have been demonstrated for GENOTROPIN and/or pituitary growth hormone:
Skeletal Growth: GENOTROPIN stimulates skeletal growth in children with GHD. The measurable increase in body length after administration of either GENOTROPIN or pituitary growth hormone results from an effect on the epiphyseal plates of long bones. Concentrations of IGF-I, which may play a role in skeletal growth, are generally low in the serum of GHD children but tend to increase during treatment with GENOTROPIN. Elevations in mean serum alkaline phosphatase concentration are also seen.
Cell Growth: It has been shown that there are fewer skeletal muscle cells in short statured children who lack endogenous growth hormone as compared with normal children. Treatment with Somatropin for Injection results in an increase in both the number and size of muscle cells.
Linear growth is facilitated in part by increased cellular protein synthesis. Nitrogen retention, as demonstrated by decreased urinary nitrogen excretion and serum urea nitrogen, follows the initiation of therapy with pituitary growth hormone. Treatment with GENOTROPIN results in a similar decrease in serum urea nitrogen. In adults with GHD, treatment with GENOTROPIN increases protein synthesis and increases overall lean body mass.
Children with hypopituitarism sometimes experience fasting hypoglycemia that is improved by treatment with GENOTROPIN. Large doses of human growth hormone may impair glucose tolerance.
In GHD patients, administration of recombinant somatropin has resulted in lipid mobilization, reduction in body fat stores, and increased plasma fatty acids.
Somatropin induces retention of sodium, potassium, and phosphorus. Retention of sodium, potassium, and phosphorus is induced by pituitary growth hormone in children. In treated adults, osteocalcin and procollagen levels are significantly increased. Serum concentrations of inorganic phosphate are increased in patients with GHD after therapy with GENOTROPIN or pituitary growth hormone. Serum calcium is not significantly altered by either GENOTROPIN or pituitary growth hormone. Growth hormone could increase calciuria.
Quality of Life as measured by the Nottingham Health Profile showed significant improvements in “energy” and “sleep” in the GH-treated group in comparison with the placebo group. The total well-being score, produced by the Psychological General Well-Being Scale, was significantly better for the GH-group than for the placebo group. For “anxiety”, “depression” and “positive well-being” a trend towards improvement was found in the GH treated group but the effect was not statistically significant.
There is no apparent difference in the positive growth response to GENOTROPIN administered by either the IM or SC route when the frequency of dosing is the same.
When the relative bioavailability was compared with the reference (Kabi-Vial 4 IU) at a common dose of 0.1 IU/kg, both MiniQuick formulations (0.4 mg and 2.0 mg) met the standards for bioequivalence as stated in the Canadian guidance document, Comparative Bioavailability Standards: Formulations Used for Systemic Effects.
The pharmacokinetic profile after an intramuscular injection (IM) is similar to SC injection. No significant differences have been noted in Tmax, Cmax or area under the curve between these two routes of administration.
Approximately 80% of GENOTROPIN is absorbed following subcutaneous (SC) injection. Maximum serum concentrations are achieved 3 - 4 hours following SC injection.
Before reconstitution: Keep refrigerated. Store at 2°C – 8°C until expiry. Do not freeze. Do not shake. Keep the GoQuick pen in the outer carton in order to protect from light.
The GoQuick pen can be stored for a maximum of 4 weeks unrefrigerated (at or below 25°C). During and/or at the end of the 4 weeks period, the product should not be put back in the refrigerator. After this 4 week period, the GoQuick pen must be discarded.
After reconstitution: Keep refrigerated. Store at 2°C – 8°C for a maximum of 4 weeks. Do not freeze. Do not shake. Keep the reconstituted GoQuick pen in the outer carton in order to protect from light.
Once removed from the refrigerator, the reconstituted solution can remain at room temperature for up to 2 hours prior to each injection. Once the injection is administered, the reconstituted solution must be returned to the refrigerator. The cycle can be repeated over the allowable 4 week period.
Before reconstitution: Keep refrigerated. Store at 2ºC – 8ºC until expiry. Do not freeze. Do not shake. Keep the MiniQuick syringe in the outer carton in order to protect from light.
The MiniQuick syringe can be stored for a maximum of 6 months unrefrigerated (at or below 25°C). During and/or at the end of this 6 months period, the product should not be put back in the refrigerator.After this, the MiniQuick syringe must be discarded.
After reconstitution:Use immediately or store in a refrigerator at 2ºC – 8ºC and use within 24 hours. Do not freeze. Do not shake. Keep the MiniQuick syringe in the outer carton in order to protect from light.
Growth Hormone Delivery Device containing a two-chamber cartridge of GENOTROPIN (with preservative)The 5 mg pre-filled pen GoQuick is colour coded green.The 5.3 mg pre-filled pen GoQuick is colour coded blue.The 12 mg pre-filled pen GoQuick is colour coded purple.
5.0, 5.3 and 12 mg: Packages of 1s and Packages of 5s
Not all pack sizes and strengths may be marketed in Canada.
Growth Hormone Delivery Device containing a two-chamber cartridge of GENOTROPIN (without preservative)
1.2, 1.6, 1.8 and 2.0 mg: Packages of 4s0.2, 0.4, 0.6, 0.8, 1.0, 1.2, 1.4, 1.6, 1.8, and 2.0 mg: Packages of 7s and Packages of 28 (4 x 7 Packages)
Not all package sizes and strengths may be marketed in Canada.
Please see directions for use accompanying each delivery device.
GENOTROPIN (somatropin for injection) is a sterile white lyophilized powder containing (or of) highly purified rhGH, intended for subcutaneous injection.
The reconstituted recombinant somatropin solution has an osmolality of approximately 300 mOsm/kg, and a pH of approximately 6.7. The concentration of the reconstituted solution varies by strength and presentation.
Powder and 1.14 ml liquid in a two-chamber glass cartridge (type I glass) separated by a rubber plunger (bromobutyl). The cartridge is sealed at one end with a rubber disc (bromobutyl) and an aluminium cap and at the other end by a rubber stopper (bromobutyl). The two-chamber cartridge is supplied for use in a disposable multidose pre-filled pen. The 5 mg, 5.3mg and 12 mg presentations of GENOTROPIN GoQuick lyophilized powder contain m-cresol as a preservative. These products should not be used by patients with a known sensitivity to this preservative.
Powder and 0.275 - 0.282 ml liquid in a two chamber glass cartridge (type I glass) separated by a rubber plunger (bromobutyl), supplied as a single dose syringe. The cartridge is sealed at both ends with rubber stoppers (bromobutyl) and is enclosed in a plastic sleeve with a plunger rod and a finger grip. The GENOTROPIN MiniQuick presentations are preservative-free.
Quantity per Syringe
0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1.0 mg, 1.2 mg, 1.4 mg, 1.6 mg, 1.8 mg, and 2.0 mg/syringe
0.22 mg - 2.26 mg Somatropin for Injection
0.23 - 0.24 mg glycine
13.8 - 14.1 mg mannitol
0.050 - 0.051 mg sodium dihydrogen phosphate anhydrous
0.027 - 0.028 mg disodium phosphate anhydrous
to 0.28 mL Water for injection
Quantity per mL
5.0 -5.3 mg Somatropin for Injection
2 mg glycine
41 mg mannitol
0.29 mg sodium dihydrogen phosphate anhydrous
0.28 mg disodium phosphate anhydrous
3 mg metacresol
to 1 mL Water for injection
12.0 mg Somatropin for Injection
40 mg mannitol
0.41 mg sodium dihydrogen phosphate anhydrous
0.40 mg disodium phosphate anhydrous
Control #: 229726 L3 July 28, 2020
*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product:
1 866 723-7111.
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
You may also contact the Canada Vigilance Program directly to report adverse events or product quality concerns at